Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
postprandial glucose
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "postprandial glucose" in MCE Product Catalog:
7
7 Publications Verification
Synonyms: Duvoglustat
Category:
Alkaloids Piperidine Alkaloids Metabolic Disease Plants Moraceae Disease Research Fields Morus alba Linn.
Target:
7
7 Publications Verification
Synonyms: Duvoglustat hydrochloride
Category:
Commelinaceae Commelina communis L. Metabolic Disease Plants Disease Research Fields Saccharides Monosaccharides
Target:
5
5 Cited Publications
Cat. No.: HY-17638
CAS No.: 666843-10-3
Synonyms: DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base
Target:
Research Areas:
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .
4
4 Cited Publications
Cat. No.: HY-N2593
CAS No.: 32507-66-7
2
2 Cited Publications
Synonyms: Quercetin-7-O-β-D-glucopyranoside
Category:
Flavonols Ginkgoaceae Metabolic Disease Plants Compositae Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Derris scandens Ginkgo biloba L. Disease Research Fields
Target:
1
1 Cited Publications
Cat. No.: HY-P2080B
Target:
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
DBPR108 is an orally active, selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 of 15 nM. DBPR108 reduces glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose levels, increases serum active GLP-1 and insulin levels, and improves glucose tolerance. DBPR108 can be used in research related to type 2 diabetes .
Cat. No.: HY-175701
CAS No.: 2810808-95-6
Synonyms: RO7795081; RG6652
Target:
Research Areas:
CT-996 is an orally active GLP-1RA agonist with an EC50 of 0.49 nM. CT-996 reduces the recruitment of β-arrestin and the internalization of GLP-1R. CT-996 suppresses postprandial blood glucose in mice expressing human GLP-1 receptors and enhances glucose-stimulated insulin secretion (GSIS) in obese monkeys during intravenous glucose challenge. CT-996 can be used for the research of type 2 diabetes (T2D) and obesity .
Category:
Metabolic Disease Endogenous metabolite Disease Research Fields Sweeteners Saccharides Food Research Monosaccharides
Target:
Cat. No.: HY-120565
CAS No.: 1594041-84-5
Research Areas:
WB403 is an orally active TGR5 activator with an EC50 of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes .
Cat. No.: HY-W145497
CAS No.: 3615-56-3
Target:
Research Areas:
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus .
Cat. No.: HY-14860R
CAS No.: 19130-96-2
Synonyms: Duvoglustat (Standard)
Target:
Cat. No.: HY-P5390A
Target:
Research Areas:
Cat. No.: HY-P5390
Target:
Research Areas:
Cat. No.: HY-P2080
CAS No.: 198624-01-0
Target:
Research Areas:
Cat. No.: HY-P2080C
Target:
Research Areas:
Cat. No.: HY-172757
Target:
Research Areas:
α-Glucosidase-IN-88 (Compound 3K) is an orally active and potent α-glucosidase inhibitor with an IC50 value of 6.40 µM. α-Glucosidase-IN-88 inhibits carbohydrate hydrolysis by blocking the enzyme's ability to break down glycosidic bonds, thereby reducing postprandial blood glucose levels. α-Glucosidase-IN-88 is promising for research of type 2 diabetes mellitus (T2DM) .
Cat. No.: HY-19904A
CAS No.: 872260-47-4
Synonyms: (+/-)-LY2409021
Target:
Research Areas:
(+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .
Cat. No.: HY-42680S
CAS No.: 478506-42-2
Synonyms: D-(-)-Tagatose-13C
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
